1. Medtech Insight
  2. >>Business
  3. >>Deals

Veracyte Expands Into Urologic Cancer Testing By Acquiring Decipher For $600M

 
• By Reed Miller

With the addition of Decipher, Veracyte now offers tests for seven of the 10 most common types of cancer in the US.

Close up female doctor wearing face mask consulting mature patient
• Source: shutterstock.com

Veracyte is adding urologic cancer tests to its genomics testing portfolio with the acquisition of Decipher Biosciences.

Veracyte acquired Decipher for $600m in cash, the companies announced on 15 March. San Diego-based Decipher will be a wholly owned subsidiary of South San Francisco-based Veracyte.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.